NOCIL NOCIL Q3 FY26 results (Oct–Dec 2025) and concall
NOCIL reported a mixed Q3 FY26, with domestic volumes showing high single-digit growth, contributing to a stable quarterly revenue of Rs. 316 crores and an improved operating EBITDA of Rs. 27 crores. However, international markets faced headwinds from seasonal effects and U.S. tariffs, leading to lower price realizations and a sequential decline in PBT and PAT. The company is progressing with its TDQ antioxidant expansion and expects significant volume and margin improvements in the coming years, supported by antidumping measures and new product introductions.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 0.6%, net profit down 30.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 363 | 318 | 340 | 336 | 321 −12% | 316 −1% |
| EBITDA | 38 | 24 | 34 | 31 | 22 −42% | 27 +13% |
| Net profit | 42 | 13 | 21 | 17 | 12 −71% | 9 −31% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
